Baoqing Chen1, Mihnea P Dragomir2, Linda Fabris3, Recep Bayraktar3, Erik Knutsen4, Xu Liu5, Changyan Tang6, Yongfeng Li3, Tadanobu Shimura7, Tina Catela Ivkovic8, Mireia Cruz De Los Santos3, Simone Anfossi3, Masayoshi Shimizu3, Maitri Y Shah3, Hui Ling3, Peng Shen9, Asha S Multani10, Barbara Pardini3, Jared K Burks11, Hiroyuki Katayama12, Lucas C Reineke13, Longfei Huo14, Muddassir Syed15, Shumei Song14, Manuela Ferracin15, Eiji Oki16, Bastian Fromm17, Cristina Ivan18, Krithika Bhuvaneshwar19, Yuriy Gusev19, Koshi Mimori20, David Menter14, Subrata Sen21, Takatoshi Matsuyama22, Hiroyuki Uetake23, Catalin Vasilescu24, Scott Kopetz14, Jan Parker-Thornburg10, Ayumu Taguchi21, Samir M Hanash12, Leonard Girnita25, Ondrej Slaby26, Ajay Goel7, Gabriele Varani6, Mihai Gagea27, Chunlai Li28, Jaffer A Ajani29, George A Calin30. 1. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. 2. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of General Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 3. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway. 5. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 6. Department of Chemistry, University of Washington, Seattle, Washington. 7. Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas. 8. Central European Institute of Technology, Masaryk University, Brno, Czech Republic. 9. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. 10. Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 11. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 12. Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas. 13. Department of Neuroscience, Baylor College of Medicine, Houston, Texas. 14. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 15. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. 16. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 17. Science for Life Laboratory, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 18. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas. 19. Innovation Center for Biomedical Informatics, Georgetown University, Washington, District of Columbia. 20. Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan. 21. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 22. Department of Gastrointestinal Surgery, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan. 23. Department of Specialized Surgeries, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan. 24. Department of General Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 25. Department of Oncology-Pathology, Bioclinicum, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden. 26. Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 27. Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 28. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: CLi10@mdanderson.org. 29. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jajani@mdanderson.org. 30. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: gcalin@mdanderson.org.
Abstract
BACKGROUND & AIMS: Chromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which encodes a long noncoding RNA (lncRNA), associates with CIN, but little is known about how CCAT2 lncRNA regulates this cancer enabling characteristic. METHODS: We performed cytogenetic analysis of colorectal cancer (CRC) cell lines (HCT116, KM12C/SM, and HT29) overexpressing CCAT2 and colon organoids from C57BL/6N mice with the CCAT2 transgene and without (controls). CRC cells were also analyzed by immunofluorescence microscopy, γ-H2AX, and senescence assays. CCAT2 transgene and control mice were given azoxymethane and dextran sulfate sodium to induce colon tumors. We performed gene expression array and mass spectrometry to detect downstream targets of CCAT2 lncRNA. We characterized interactions between CCAT2 with downstream proteins using MS2 pull-down, RNA immunoprecipitation, and selective 2'-hydroxyl acylation analyzed by primer extension analyses. Downstream proteins were overexpressed in CRC cells and analyzed for CIN. Gene expression levels were measured in CRC and non-tumor tissues from 5 cohorts, comprising more than 900 patients. RESULTS: High expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin. Mice that expressed the CCAT2 transgene developed chromosome abnormalities, and colon organoids derived from crypt cells of these mice had a higher percentage of chromosome abnormalities compared with organoids from control mice. The transgenic mice given azoxymethane and dextran sulfate sodium developed more and larger colon polyps than control mice given these agents. Microarray analysis and mass spectrometry indicated that expression of CCAT2 increased expression of genes involved in ribosome biogenesis and protein synthesis. CCAT2 lncRNA interacted directly with and stabilized BOP1 ribosomal biogenesis factor (BOP1). CCAT2 also increased expression of MYC, which activated expression of BOP1. Overexpression of BOP1 in CRC cell lines resulted in chromosomal missegregation errors, and increased colony formation, and invasiveness, whereas BOP1 knockdown reduced viability. BOP1 promoted CIN by increasing the active form of aurora kinase B, which regulates chromosomal segregation. BOP1 was overexpressed in polyp tissues from CCAT2 transgenic mice compared with healthy tissue. CCAT2 lncRNA and BOP1 mRNA or protein were all increased in microsatellite stable tumors (characterized by CIN), but not in tumors with microsatellite instability compared with nontumor tissues. Increased levels of CCAT2 lncRNA and BOP1 mRNA correlated with each other and with shorter survival times of patients. CONCLUSIONS: We found that overexpression of CCAT2 in colon cells promotes CIN and carcinogenesis by stabilizing and inducing expression of BOP1 an activator of aurora kinase B. Strategies to target this pathway might be developed for treatment of patients with microsatellite stable colorectal tumors.
BACKGROUND & AIMS: Chromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which encodes a long noncoding RNA (lncRNA), associates with CIN, but little is known about how CCAT2 lncRNA regulates this cancer enabling characteristic. METHODS: We performed cytogenetic analysis of colorectal cancer (CRC) cell lines (HCT116, KM12C/SM, and HT29) overexpressing CCAT2 and colon organoids from C57BL/6N mice with the CCAT2 transgene and without (controls). CRC cells were also analyzed by immunofluorescence microscopy, γ-H2AX, and senescence assays. CCAT2 transgene and control mice were given azoxymethane and dextran sulfate sodium to induce colon tumors. We performed gene expression array and mass spectrometry to detect downstream targets of CCAT2 lncRNA. We characterized interactions between CCAT2 with downstream proteins using MS2 pull-down, RNA immunoprecipitation, and selective 2'-hydroxyl acylation analyzed by primer extension analyses. Downstream proteins were overexpressed in CRC cells and analyzed for CIN. Gene expression levels were measured in CRC and non-tumor tissues from 5 cohorts, comprising more than 900 patients. RESULTS: High expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin. Mice that expressed the CCAT2 transgene developed chromosome abnormalities, and colon organoids derived from crypt cells of these mice had a higher percentage of chromosome abnormalities compared with organoids from control mice. The transgenic mice given azoxymethane and dextran sulfate sodium developed more and larger colon polyps than control mice given these agents. Microarray analysis and mass spectrometry indicated that expression of CCAT2 increased expression of genes involved in ribosome biogenesis and protein synthesis. CCAT2 lncRNA interacted directly with and stabilized BOP1 ribosomal biogenesis factor (BOP1). CCAT2 also increased expression of MYC, which activated expression of BOP1. Overexpression of BOP1 in CRC cell lines resulted in chromosomal missegregation errors, and increased colony formation, and invasiveness, whereas BOP1 knockdown reduced viability. BOP1 promoted CIN by increasing the active form of aurora kinase B, which regulates chromosomal segregation. BOP1 was overexpressed in polyp tissues from CCAT2transgenic mice compared with healthy tissue. CCAT2 lncRNA and BOP1 mRNA or protein were all increased in microsatellite stable tumors (characterized by CIN), but not in tumors with microsatellite instability compared with nontumor tissues. Increased levels of CCAT2 lncRNA and BOP1 mRNA correlated with each other and with shorter survival times of patients. CONCLUSIONS: We found that overexpression of CCAT2 in colon cells promotes CIN and carcinogenesis by stabilizing and inducing expression of BOP1 an activator of aurora kinase B. Strategies to target this pathway might be developed for treatment of patients with microsatellite stable colorectal tumors.
Authors: W James Kent; Charles W Sugnet; Terrence S Furey; Krishna M Roskin; Tom H Pringle; Alan M Zahler; David Haussler Journal: Genome Res Date: 2002-06 Impact factor: 9.043
Authors: Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm Journal: Nat Med Date: 2011-10-23 Impact factor: 53.440
Authors: Jane Bayani; Shamini Selvarajah; Georges Maire; Bisera Vukovic; Khaldoun Al-Romaih; Maria Zielenska; Jeremy A Squire Journal: Semin Cancer Biol Date: 2006-10-26 Impact factor: 15.707
Authors: Maitri Y Shah; Manuela Ferracin; Valentina Pileczki; Baoqing Chen; Roxana Redis; Linda Fabris; Xinna Zhang; Cristina Ivan; Masayoshi Shimizu; Cristian Rodriguez-Aguayo; Mihnea Dragomir; Katrien Van Roosbroeck; Maria Ines Almeida; Maria Ciccone; Daniela Nedelcu; Maria Angelica Cortez; Taghi Manshouri; Steliana Calin; Muharrem Muftuoglu; Pinaki P Banerjee; Mustafa H Badiwi; Jan Parker-Thornburg; Asha Multani; James William Welsh; Marcos Roberto Estecio; Hui Ling; Ciprian Tomuleasa; Delia Dima; Hui Yang; Hector Alvarez; M James You; Milan Radovich; Elizabeth Shpall; Muller Fabbri; Katy Rezvani; Leonard Girnita; Ioana Berindan-Neagoe; Anirban Maitra; Srdan Verstovsek; Riccardo Fodde; Carlos Bueso-Ramos; Mihai Gagea; Guillermo Garcia Manero; George A Calin Journal: Genome Res Date: 2018-03-22 Impact factor: 9.043
Authors: Zhang Huan; Zhu Mei; Huang Na; Ma Xinxin; Wang Yaping; Liu Ling; Wang Lei; Zhang Kejin; Liu Yanan Journal: Neurochem Res Date: 2021-01-29 Impact factor: 3.996